Open AccessResponse to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases
Author(s) -
Robin Guo,
Mark Schreyer,
Jason C. Chang,
S. Michael Rothenberg,
Dahlia Henry,
Paolo Cotzia,
Mark G. Kris,
Natasha Rekhtman,
Robert J. Young,
David M. Hyman,
Alexander Drilon
Publication year - 2019
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.19.00021
Subject(s) - medicine , cabozantinib , oncology , vandetanib , clinical trial , lung cancer , targeted therapy , cancer , disease , chemotherapy , sorafenib , hepatocellular carcinoma
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom